|
Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
Sep 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
May 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Advancing drug development in myelodysplastic syndromes |
Mar 2025 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Alcohol use is not a significant contributor to myelodysplastic syndromes |
Apr 2020 |
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
Jun 2023 |
American Journal of Hematology |
Aplastic Anemia |
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
Apr 2023 |
American Journal of Hematology |
Aplastic Anemia |
|
Allogeneic bone marrow transplantation for aplastic anemia |
Dec 2022 |
International Journal of Hematology |
Aplastic Anemia |
|
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy |
Sep 2024 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
|
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review |
Jun 2025 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse |
Jan 2021 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
